Sedia's single-use, qualitative immunoassay, called the Asanté HIV-1/2 Oral Fluid Test, detects antibodies to HIV-1 and HIV-2 using oral fluids in as little as 20 minutes and is intended for use by ...

President and CEO Jim Davis said he believes PAMA reform will pass this year but said another temporary delay will likely be needed to postpone cuts slated for February 1.

The physical and digital biobank supports the integration of artificial intelligence in acute care diagnostics development.

Last week, readers were most interested in a story about concerns about BillionToOne's Unity NIPT due to false negative results.

The tests run on the company's TruVerus benchtop instrument, which provides results from a blood sample in minutes.

For full-year 2025, MDxHealth's preliminary revenues are $109 million, up 21 percent from 90.0 million in 2024. It billed 49,180 tissue-based units, up from 18 percent year over year, and 71,920 ...

The company said its preliminary revenues for the fourth quarter were at least $21 million, and its full-year 2025 revenues are expected to grow to $77 million.

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.

The firm has developed a whole-blood mRNA test intended for use as a screening tool in women at elevated risk of breast cancer.

The companies will work to integrate Prevencio's protein-based blood tests into Quadrant's care pathways to better translate the results into clinical action and measure outcomes.

The deal makes Guardant's blood-based colorectal cancer screening test available to active duty US military members.